Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Semafore Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Semafore Pharmaceuticals Inc. (formerly ComChem Technologies) didn't start with a breakthrough scientific discovery. But the firm's founders encountered a unique opportunity along the way-through the work of Donald Durden, MD, PhD, at the Indiana University School of Medicine-and took advantage of it. Now Semafore is discovering and developing novel small molecules to treat cancer by targeting what the founders believe is the primary, non-redundant cell-signaling pathway for controlling cell survival and cell death.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts